Panic Disorder
📧 Sign up to get email alerts when something new happens for Panic Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-06-09FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for sertraline hydrochloride (generic) from Quallent Pharmaceuticals Health LLC under ANDA077397.
-
FDA approval · 2015-05-28FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (Yaopharma Co., Ltd.)
FDA approved Yaopharma Co., Ltd.'s original application for venlafaxine hydrochloride, authorizing a new generic version of the antidepressa…
-
FDA approval · 2015-05-18FDA Approved: CLONAZEPAM — Supplemental Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare Inc.'s Supplemental Application for clonazepam, making a supplemental approval under the approved ANDA. Clona…
-
FDA approval · 2015-05-01FDA Approved: VENLAFAXINE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for Venlafaxine from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. under an ANDA.
-
FDA approval · 2015-03-16FDA Approved: FLUOXETINE — Original Application (Vensun Pharmaceuticals, Inc.)
The FDA approved Vensun Pharmaceuticals' original (ANDA) application for fluoxetine hydrochloride, establishing a generic fluoxetine product…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-03-05Clinical Trial Update: Effectiveness of Cognitive Behavioral Therapy With Panic Control Treatment for Adolescents With Panic Disorder [Phase 2]
A Phase 2 trial update assesses the effectiveness of Cognitive Behavioral Therapy with Panic Control Treatment in adolescents with panic dis…
-
CLINICAL_TRIALS research · 2015-02-09Clinical Trial Update: Physical Activity and Cognitive Behavioural Therapy in Panic Disorder and Agoraphobia [NA]
This clinical trial update notes the completion of a study evaluating physical activity plus cognitive behavioral therapy for Panic Disorder…
-
CLINICAL_TRIALS research · 2015-02-06Clinical Trial Update: Threat-Avoidance Learning in Anxiety Patients
KU Leuven reports a clinical trial update on threat-avoidance learning in anxiety patients, focusing on panic disorder, phobias, and PTSD; t…
-
FDA approval · 2015-02-03FDA Approved: KLONOPIN — Supplemental Application (H2-Pharma, LLC)
The FDA approved a supplemental application for KLONOPIN (clonazepam) filed by H2-Pharma, LLC.
-
CLINICAL_TRIALS trial_result · 2015-01-13Clinical Trial Update: Exposure Therapy for Veterans With PTSD and Panic Attacks (Phase 1) [Phase 1]
Phase 1 trial evaluating exposure therapy for veterans with post-traumatic stress disorder and panic attacks; results were posted in 2015.
-
FDA approval · 2015-01-12FDA Approved: FLUOXETINE — Supplemental Application (Chartwell Governmental & Specialty RX, LLC)
FDA approved a supplemental application for a generic fluoxetine product (ANDA 076458) from Chartwell Governmental & Specialty RX, LLC. This…
-
FDA approval · 2014-12-17FDA Approved: EFFEXOR XR — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Effexor XR (venlafaxine hydrochloride) by Viatris Specialty LLC. The action is to modify labelin…
-
FDA approval · 2014-12-01FDA Approved: PAROXETINE — Supplemental Application (Padagis US LLC)
FDA approved a supplemental application for paroxetine submitted by Padagis US LLC, adding or updating labeling under the existing NDA.
-
FDA approval · 2014-11-26FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for PAROXETINE (paroxetine hydrochloride) from Zydus Lifesciences Limited, enabling the marketing of…
-
FDA approval · 2014-11-17FDA Approved: VENLAFAXINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approval of a supplemental application for Venlafaxine from Sun Pharmaceutical Industries, confirming regulatory action on this generic …
-
FDA approval · 2014-11-07FDA Approved: SERTRALINE HYDROCHLORIDE — Original Application (Accord Healthcare, Inc.)
FDA approves Accord Healthcare, Inc.'s generic sertraline hydrochloride under an Original Application (ANDA 202825).
-
FDA approval · 2014-10-31FDA Approved: ALPRAZOLAM — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for Alprazolam submitted by Sandoz Inc, related to a generic version of the drug.
-
FDA approval · 2014-10-31FDA Approved: PAROXETINE — Original Application (Solco Healthcare US, LLC)
FDA approved Solco Healthcare US, LLC's original ANDA for paroxetine hydrochloride hemihydrate (paroxetine), making a generic version of the…
-
FDA approval · 2014-10-27FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for sertraline hydrochloride, a generic version of sertraline. This action …
-
FDA approval · 2014-10-21FDA Approved: EFFEXOR XR — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Effexor XR (venlafaxine extended-release) submitted by Viatris Specialty LLC.
-
FDA approval · 2014-10-17FDA Approved: FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved Teva Pharmaceuticals USA, Inc.'s supplemental application for fluoxetine.
-
FDA approval · 2014-10-10FDA Approved: PROZAC — Supplemental Application (Dista Products Company)
FDA approved a supplemental application for Prozac (fluoxetine hydrochloride) submitted by Dista Products Company.
-
CLINICAL_TRIALS trial_result · 2014-09-25Clinical Trial Update: A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients [Phase 4]
Phase 4 clinical trial evaluating a collaborative care program to improve treatment of depression and anxiety disorders in patients with hea…
-
CLINICAL_TRIALS trial_result · 2014-09-22Clinical Trial Update: Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression [Phase 2]
Phase 2 clinical trial evaluating repetitive transcranial magnetic stimulation (rTMS) for panic disorder with comorbid major depressive diso…
-
FDA approval · 2014-09-19FDA Approved: VENLAFAXINE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approved a supplemental application for venlafaxine by Alembic Pharmaceuticals, enabling a generic venlafaxine product through an ANDA s…